Novo Nordisk's weight loss and diabetes drugs, Ozempic and Wegovy, are under scrutiny due to reports of causing stomach paralysis in some users. The U.S. Food and Drug Administration (FDA) has received reports of this side effect, and some cases persist even after discontinuing the drugs. Despite these complications, the FDA maintains that the benefits of the medication might still outweigh its risks. The American Society of Anesthesiologists recently warned of the increased risk of patients regurgitating food during surgery due to Novo's medications.